Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of Toronto

$15,000.00

Market research proposal for a cell-free protein manufacturing system

FY 2019-20

Summary
Recent biomedical advancements are revolutionizing the way we approach patient health. However, the exorbitant costs associated with many protein-based laboratory reagents limit the rate of progress in biomedicine. This is particularly true for regenerative medicine research, where access to cytokines, antibodies and growth factors is hampered by the extremely high market price of these reagents. We have created an automated cell-free protein manufacturing platform that can rapidly produce and purify proteins, including cytokines, antibodies and growth factors, at any scale and within a few hours. This is in contrast with current cell-based technologies that could take weeks to express and purify a desired protein, and that require large upfront investments regardless of scale. Our automated cell-free manufacturing platform allows just-in-time production and agile scaling, which significantly minimizes our capital and inventory costs. This, in turn, means that end users can have access to a large library of laboratory reagents such as cytokines, antibodies and growth factors at a fraction of their current market price. It also means that they can readily modify their desired proteins with fusion tags (e.g. for purification or fluorescence) that suit their specific experiments and protocols.This is an application for an I2I Market Assessment grant. The goal of this Assessment is to reach out to the industry and potential customers to identify customer needs and target markets. This will help inform and articulate our value proposition, which will allow us to optimize our market entry strategy for successful commercialization of our technology.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
548735-2020
Name nom
Pardee, Keith
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2020
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Market research proposal for a cell-free protein manufacturing system
Keyword
NSERC
Application summary
Recent biomedical advancements are revolutionizing the way we approach patient health. However, the exorbitant costs associated with many protein-based laboratory reagents limit the rate of progress in biomedicine. This is particularly true for regenerative medicine research, where access to cytokines, antibodies and growth factors is hampered by the extremely high market price of these reagents. We have created an automated cell-free protein manufacturing platform that can rapidly produce and purify proteins, including cytokines, antibodies and growth factors, at any scale and within a few hours. This is in contrast with current cell-based technologies that could take weeks to express and purify a desired protein, and that require large upfront investments regardless of scale. Our automated cell-free manufacturing platform allows just-in-time production and agile scaling, which significantly minimizes our capital and inventory costs. This, in turn, means that end users can have access to a large library of laboratory reagents such as cytokines, antibodies and growth factors at a fraction of their current market price. It also means that they can readily modify their desired proteins with fusion tags (e.g. for purification or fluorescence) that suit their specific experiments and protocols.This is an application for an I2I Market Assessment grant. The goal of this Assessment is to reach out to the industry and potential customers to identify customer needs and target markets. This will help inform and articulate our value proposition, which will allow us to optimize our market entry strategy for successful commercialization of our technology.